Marché de la protection des cultures à base de peptides Taille et part 2026-2035

Peptide-Based Crop Protection Market Size

The peptide-based crop protection market was valued at $285 Million in 2025 and is projected to reach $1.6 Billion by 2035, expanding at an 18.9% CAGR from the base year; the website convention, which measures from the first forecast year, is 19.3% for 2026-2035.

Its commercial boundary is narrower than biological crop protection overall. It includes products whose primary protective mechanism is a defined peptide or lipopeptide active, whether natural/bio-derived, recombinant, or synthetic. This captures fermentation-derived lipopeptide fungicides, insecticidal peptides, plant-defense elicitors, antibacterial and nematicidal peptides, and emerging herbicidal micropeptides. It excludes biological products whose contribution cannot be credibly tied to a peptide-active mechanism.

The present market is economically anchored by antifungal lipopeptides, while its growth premium is tied to new modes of action and delivery formats. The U.S. EPA maintains distinct registration considerations for biopesticides, including biochemical products, which makes regulatory classification a material commercial gate rather than a procedural detail ^{[1]U.S. Environmental Protection Agency, Pesticide Registration Manual: Chapter 3 - Additional Considerations for Biopesticide Products. epa.gov}. BASIN, Vestaron's peptide bioinsecticide active ingredient, received EPA registration in March 2024, demonstrating a route to commercialization for a novel peptide active ^{[2]Vestaron Corporation, Advancing Peptide-Based Technology with Regulatory Breakthroughs. vestaron.com}.

Antifungal peptides account for $228.9 Million of 2025 revenue, whereas insecticidal peptides account for $14.8 Million and herbicidal peptides $4.0M. The difference matters: established fermentation products support the market base, but the forecast increasingly depends on product classes with more limited operating histories. Vestaron leads the market with an 11.4% share in 2025. Vestaron, Syngenta, BASF, Bayer, and FMC collectively hold 47.7%, leaving substantial room for specialized biological suppliers and pre-commercial innovators.

The forecast also contains unequal confidence. Herbicidal peptides carry a 46.1% CAGR from a $4.0 Million base, but the category remains low-medium confidence because commercial scale depends on timely registration and field performance of pipeline products. A delay in those gates would not negate the market's antifungal base; it would change the composition and timing of growth. Buyers and investors should therefore separate dependable expansion in established lipopeptide programs from option value in emerging insecticidal and herbicidal platforms.

Key Drivers

Regulatory mandates for chemical pesticide reduction. Regulation creates demand only when it changes the economics of a grower's crop-protection program. Europe's Farm to Fork policy frames a 2030 reduction ambition for chemical pesticides, increasing the strategic importance of effective biological alternatives in integrated pest management ^{[3]European Parliament, The Farm to Fork Strategy. europarl.europa.eu}. In the United States, the biopesticide registration framework offers a differentiated route for products that meet its criteria. In China, policy support for green pest control and biological pesticide development broadens the institutional setting for lower-risk products ^{[4]Global Agriculture, China's MARA to Streamline Approval and Promote High-Efficiency Bio-Pesticides. global-agriculture.com}. These measures favor peptide products where a defined active ingredient can be incorporated into documented IPM protocols rather than used as an undifferentiated biological input.

Resistance management and novel-mode-of-action premiums. Antimicrobial peptides can disrupt membranes and related cellular functions through mechanisms that differ from many single-site synthetic products. That biological distinction has commercial value when growers need rotation options rather than another product with overlapping resistance exposure. Vestaron's SPEAR LEP and BASIN platforms illustrate the more immediate opportunity: a registered peptide insecticide can be positioned in lepidopteran programs where resistance management, residue constraints, and preharvest timing are considered together. The premium is strongest where field efficacy and label fit justify replacement or rotation, not simply where resistance has been documented.

Specialty-crop procurement and residue constraints. Fruits and vegetables account for $135.4 Million of 2025 market revenue. These crops support higher per-hectare input economics and face more frequent residue, harvest-timing, and export-market constraints than broad-acre commodity crops. The commercial consequence is that peptide products can establish themselves first where a program's compliance value offsets a higher cost per treated area. This creates a pragmatic route to scale, while also limiting near-term penetration in crops with lower gross margins.

Key Restraints

Manufacturing economics remain a boundary on addressable acreage. Solid-phase peptide synthesis can offer sequence control but does not automatically produce agricultural cost competitiveness. Fermentation and recombinant production can improve the equation for particular peptides, yet formulation stability, dose, and application frequency still determine the delivered cost per hectare. Vestaron's manufacturing collaboration with AD Million is significant because it addresses production scale, a bottleneck that a regulatory approval alone does not resolve. Until manufacturing economics improve, the clearest fit remains specialty crops and targeted uses rather than broad substitution in commodity grains and oilseeds.

Novel-active registration is a multi-stage commercial risk. EPA guidance differentiates biopesticide registration requirements, but developers still need adequate identity, performance, and safety evidence for a specific product. Comparable challenges arise when companies seek access across multiple jurisdictions. Micropep's EPA biochemical-like classification for MPD-01 is evidence of regulatory engagement, not a commercial registration. That distinction is crucial: development announcements expand technological possibility, but they do not create sales capacity until the product clears full regulatory and supply-chain requirements.

The constraint is not uniform across the market. Fermentation-based antifungal products already have a commercial logic, whereas new insecticidal, recombinant, and herbicidal candidates face a linked manufacturing-and-registration test. As a result, the strongest near-term opportunities are likely to be products that add a distinct role to existing IPM programs. Broad-acre adoption is more sensitive to cost per hectare and will depend on credible scale-up rather than novelty alone. The practical procurement question is whether a peptide can reduce total program risk, including resistance exposure, rejected loads, or labor constraints, rather than whether it can displace conventional chemistry acre for acre. This favors careful use-positioning and channel training over undifferentiated biological-product launches. It also makes distributor agronomy capability material: growers need label-compliant application guidance, compatible tank-mix advice, and credible performance expectations under local disease or pest pressure.

Peptide-Based Crop Protection Market Segment Analysis

Product Type.

Antifungal peptides are projected to grow from $228.9 Million in 2025 to $1,020.4 Million in 2035 at a 16.1% CAGR. Their scale is rooted in fermentation-derived lipopeptide products, including BASF's Serifel, which is based on Bacillus amyloliquefaciens MBI 600 ^{[5]BASF SE, Serifel Biological Fungicide. agriculture.basf.us}, and Bayer's Serenade portfolio, whose EPA label identifies Bacillus amyloliquefaciens strain QST 713 ^{[6]U.S. Environmental Protection Agency, Serenade ASO EPA Pesticide Product Label. epa.gov}. This category is a commercial foundation, not a stagnant legacy segment: its share declines because the total market broadens, while its absolute revenue rises materially.

Insecticidal peptides increase from $14.8 Million to $190.2 Million at a 29.1% CAGR. Their case rests on differentiated pest-control mechanisms and a small base of commercially registered products, particularly Vestaron's platform. SOLASTA Bio belongs in this segment as an insect-specific neuropeptide developer, not in antifungals; its $14 Million Series A in September 2024, led by Forbion with FMC Ventures and Corteva Catalyst participation, supports its field-stage development but does not represent product revenue. Antibacterial peptides rise from $5.7 Million to $56.4M, nematicidal peptides from $5.4 Million to $35.5M, and plant elicitor peptides from $26.2 Million to $132.2M. Plant elicitors have a distinct role: they aim to prime plant defense rather than directly replace every fungicide or insecticide application.

Herbicidal peptides rise from $4.0 Million to $177.3 Million at a 46.1% CAGR, with low-medium confidence. Micropep's MPD-01 classification and its multi-year development agreement with Corteva demonstrate interest in micropeptide discovery and commercialization pathways. They do not establish the timing or field economics of a commercial herbicidal peptide. The category's upside is therefore substantial, but it should be treated as pipeline-sensitive.

Peptide Origin & Source.

Natural/bio-derived peptides lead with $169.6 Million in 2025, reflecting the installed base of fermentation-derived lipopeptides. Recombinant peptides contribute $91.2 Million and are expected to gain relevance as insecticidal and other precision-defined actives grow. Synthetic peptides contribute $24.2M. The strategic distinction is not merely technical: origin determines the feasible production route, cost profile, and regulatory evidence required to establish consistent product identity.

Application Method.

Foliar spray is the largest method at $186.7 Million in 2025 because fungal disease and foliar insect pressure fit existing spray programs. Its 17.0% CAGR is lower than seed treatment (21.0%), soil treatment (20.9%), and other methods (24.8%). This is not a forecast of foliar decline. It indicates that delivery modes with higher dose efficiency or more targeted placement can grow faster where they match root-zone disease, early-season protection, or permanent-crop use cases. Invaio's Trecise platform illustrates the strategic interest in precision delivery for citrus, though delivery infrastructure and peptide product revenue should not be conflated.

Crop Type.

Fruits and vegetables lead at $135.4 Million in 2025 and are expected to reach $685.1 Million in 2035. Their scale reflects the ability of residue management, harvest timing, and high crop value to support a differentiated-input premium. Cereals and grains grow from $64.1 Million to $407.8M, and oilseeds and pulses from $49.9 Million to $362.7M. These broad-acre segments offer large upside, but their adoption threshold is more dependent on application economics. Turf, ornamentals, and other crops rise from $35.6 Million to $156.4M, supported by targeted disease-management uses rather than field-scale volume.

The application mix reinforces this distinction. Foliar products retain the largest installed base, whereas seed, soil, and precision-delivery approaches gain share where they reduce waste, target root-zone or vascular pathways, or fit preventive programs. Suppliers that can demonstrate a lower delivered cost per protected crop unit, rather than only a novel peptide sequence, will be better positioned to move from specialty crops into larger-acreage segments.

Peptide-Based Crop Protection Market Regional Analysis

North America

North America is the largest region, rising from $104 Million in 2025 to $507.8 Million by 2035 at a 17.2% CAGR. The United States is the core market, supported by the EPA biopesticide framework, established specialty-crop production, and the presence of Vestaron's commercial peptide insecticide platform. Canada contributes through greenhouse vegetables and cereal production. The region's lower CAGR relative to Asia Pacific reflects a larger starting base rather than weak demand; it remains a priority launch environment for products that can demonstrate label-supported performance and integration into existing IPM programs.

Europe

Europe rises from $75.5 Million to $427.2 Million at an 18.9% CAGR. Germany, the United Kingdom, France, Spain, and Italy are the principal country markets, each combining specialty production with a policy environment that raises the value of biological alternatives. Farm to Fork's pesticide-reduction agenda gives the region a durable demand rationale. However, approval complexity means that a favorable policy direction does not compress time to market for every new active. European commercialization is therefore likely to reward companies that sequence national authorizations, formulation support, and distributor capability rather than relying on a single regional launch assumption.

Asia Pacific

Asia Pacific is the fastest-growing region, increasing from $61.3 Million in 2025 to $427.2 Million by 2035 at a 21.4% CAGR. China and India are the principal scale drivers, followed by Japan, South Korea, and Australia. China's support for green pest control and biological pesticide development strengthens the adoption environment. The investment case is not simply acreage: it rests on the ability to navigate country-specific registration, build local technical support, and match product economics to diverse crop systems. That makes regional partnerships and domestic distribution more important than a broad export-only model.

Latin America

Latin America expands from $32.8 Million to $185.4 Million at an 18.9% CAGR. Brazil is the principal market, followed by Mexico and Argentina. Specialty export crops in Mexico and Brazil can support residue-sensitive programs, while soy and other broad-acre crops create a larger but more cost-sensitive opportunity. FMC's biologicals strategy and its Brazil distribution activity illustrate why established channels can be an advantage when biological portfolios broaden ^{[7]FMC Corporation, FMC Annual Report 2024. sec.gov}. The region is well suited to scale existing products, but price sensitivity will constrain peptide formats that cannot demonstrate efficient field economics.

Middle East & Africa

Middle East & Africa grows from $11.4 Million to $64.5 Million at an 18.9% CAGR. Saudi Arabia, South Africa, and the UAE are the leading country markets. Controlled-environment agriculture and export horticulture create focused demand pockets, particularly where residue and production-control requirements support premium biological programs. The region's smaller base makes selective channel development more credible than broad, capital-intensive market coverage in the near term.

Latin America offers a different route: channel depth and cost discipline may matter more than first access to novel actives. MEA is likely to remain concentrated in controlled-environment and export-oriented niches. The implication for suppliers is that a global portfolio should be sequenced by regulatory readiness and application economics: launch novel, premium products where technical service and residue value are highest, then use scale and local partnerships to extend established formats.

Peptide-Based Crop Protection Market Share & Competitive Landscape

The market is concentrated enough for large portfolios to influence channel access, yet fragmented enough for specialist technology developers to shape future category formation. The top five companies account for 47.7% of 2025 revenue, with Vestaron at 11.4%. These figures represent modeled market shares and should not be interpreted as audited company peptide revenue.

BASF SE holds an established antifungal position through Serifel and its Bacillus amyloliquefaciens MBI 600 lipopeptide platform. Bayer AG participates through the Crop Science division's Serenade portfolio; the February 2025 EPA label is evidence of continued regulatory maintenance of the product line. Syngenta AG combines biologicals commercialization with discovery capability; its acquisition of Novartis' natural-compound repository in February 2025 expanded access to microbial discovery assets relevant to biological crop protection ^{[8]Reuters, Syngenta Acquires Genetic Repository from Novartis to Boost Biologic Crop Protection. reuters.com}.

FMC Corporation participates through biological inputs and venture investments, including exposure to emerging peptide developers; its annual report identifies peptides and pheromones among strategic biological technology areas. Corteva Agriscience has a more collaborative position in the peptide market, combining biologicals activity with investments and a development agreement with Micropep. Koppert Biological Systems is a biological-control specialist whose relevance is primarily through lipopeptide-containing and broader biological programs; it is not a peptide pure-play.

Vestaron Corporation is the market leader and the most advanced pure-play commercial insecticidal peptide participant. Its portfolio includes SPEAR and BASIN products, and its manufacturing collaboration with AD Million addresses the cost-and-scale challenge that can limit novel biological actives. Its March 2025 funding round of more than $20 Million provides additional support for commercialization activity ^{[9]Vestaron Corporation, Vestaron Raises More Than $20 Million in Oversubscribed Funding Round. vestaron.com}.

Micropep Technologies is pre-commercial, with no peptide product revenue in 2025. Its $40 Million Series B and approximately $64 Million cumulative funding support platform development, while the Corteva agreement provides a potential route to agronomic trials and commercialization. SOLASTA Bio is also pre-commercial; its insect-specific neuropeptide platform and 2024 Series A position it as a future insecticidal, rather than antifungal, competitor. Invaio Sciences is relevant through programmable biologicals and precision delivery, including Trecise for citrus applications.

Genvor Incorporated is developing the pre-commercial AGM182 antifungal peptide through a USDA collaboration. Ventera Bio Ltd is an early-stage developer of venom-derived short-peptide bioinsecticide concepts. PeptechLab is an early-stage AMP crop-protection developer operating through AP Million Ventures Sp. z o.o. Peptech Biosciences Ltd. is an Indian bio-input manufacturer with Bacillus- and Btk-relevant offerings. These five firms should be evaluated on technical and regulatory milestones rather than current peptide revenue; their inclusion reflects the authorized company scope, not an assertion of comparable commercial scale.

Recent Industry Developments

In March 2024, EPA registered Vestaron's BASIN active ingredient, extending the company's commercial peptide insecticide platform. In October 2024, Vestaron announced its manufacturing collaboration with ADM, aimed at scaling production of SPEAR and BASIN active ingredients. Together, the events address two separate commercial gates: regulatory authorization and supply capacity.

Micropep received EPA biochemical-like classification for MPD-01 in January 2024. In September 2024, it announced a $40 Million Series B, and in June 2025 it entered a multi-year joint development agreement with Corteva. These are development and financing milestones, not evidence of market revenue; their relevance lies in shortening the distance between discovery and commercial validation.

SOLASTA Bio completed a $14 Million Series A in September 2024 with Forbion, FMC Ventures, and Corteva Catalyst involvement. The transaction strengthens the financing base for its insecticidal neuropeptide program. In February 2025, Syngenta agreed to acquire Novartis' natural-compound repository, adding biological discovery assets to its crop-protection pipeline.